Literature DB >> 17526829

Biofilm exclusion of uropathogenic bacteria by selected asymptomatic bacteriuria Escherichia coli strains.

Lionel Ferrières1, Viktoria Hancock1, Per Klemm1.   

Abstract

Many bacterial infections are associated with biofilm formation. In the urinary tract bacterial biofilms develop on both living surfaces and artificial implants, producing chronic and often intractable infections. Escherichia coli is the most common organism associated with urinary tract infections. In contrast to uropathogenic E. coli (UPEC), which cause symptomatic urinary tract infection, asymptomatic bacteriuria (ABU) strains are associated with essentially symptom-free infections. Here the biofilm-forming capacity on abiotic surfaces of selected E. coli ABU strains and UPEC strains in human urine was investigated. It was found that there is a strong bias for biofilm formation by the ABU strains. Not only were the ABU strains significantly better biofilm formers than UPEC strains, they were also able to out-compete UPEC strains as well as uropathogenic strains of Klebsiella spp. during biofilm formation. The results support the notion of bacterial prophylaxis employing selected ABU strains to eliminate UPEC strains and other pathogens in patients prone to recalcitrant infections.

Entities:  

Mesh:

Year:  2007        PMID: 17526829     DOI: 10.1099/mic.0.2006/004721-0

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  20 in total

1.  Contribution of siderophore systems to growth and urinary tract colonization of asymptomatic bacteriuria Escherichia coli.

Authors:  Rebecca E Watts; Makrina Totsika; Victoria L Challinor; Amanda N Mabbett; Glen C Ulett; James J De Voss; Mark A Schembri
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

Review 2.  Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Authors:  Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

3.  Functional genomics of probiotic Escherichia coli Nissle 1917 and 83972, and UPEC strain CFT073: comparison of transcriptomes, growth and biofilm formation.

Authors:  Viktoria Hancock; Rebecca Munk Vejborg; Per Klemm
Journal:  Mol Genet Genomics       Date:  2010-10-01       Impact factor: 3.291

Review 4.  Innate Immune Responses to Bladder Infection.

Authors:  Byron W Hayes; Soman N Abraham
Journal:  Microbiol Spectr       Date:  2016-12

Review 5.  Mellowing out: adaptation to commensalism by Escherichia coli asymptomatic bacteriuria strain 83972.

Authors:  Per Klemm; Viktoria Hancock; Mark A Schembri
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

6.  Inactivation of efflux pumps abolishes bacterial biofilm formation.

Authors:  Malin Kvist; Viktoria Hancock; Per Klemm
Journal:  Appl Environ Microbiol       Date:  2008-10-03       Impact factor: 4.792

7.  Biochemical detection of N-Acyl homoserine lactone from biofilm-forming uropathogenic Escherichia coli isolated from urinary tract infection samples.

Authors:  Rohollah Taghadosi; Mohammad Reza Shakibaie; Shalaleh Masoumi
Journal:  Rep Biochem Mol Biol       Date:  2015-04

Review 8.  The nature of immune responses to urinary tract infections.

Authors:  Soman N Abraham; Yuxuan Miao
Journal:  Nat Rev Immunol       Date:  2015-09-21       Impact factor: 53.106

9.  Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection.

Authors:  Thomas J Hannan; Indira U Mysorekar; Chia S Hung; Megan L Isaacson-Schmid; Scott J Hultgren
Journal:  PLoS Pathog       Date:  2010-08-12       Impact factor: 6.823

Review 10.  Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.

Authors:  Valerie P O'Brien; Thomas J Hannan; Hailyn V Nielsen; Scott J Hultgren
Journal:  Microbiol Spectr       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.